Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899402 · ClinicalTrials.gov registry record · Phase 2
Triple Therapy in T1DM
A Phase 2 study of Type 1 Diabetes Mellitus, sponsored by State University of New York at Buffalo.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT03899402 is a Phase 2 study of Type 1 Diabetes Mellitus that is active but no longer recruiting, run by State University of New York at Buffalo. The registered enrollment target is 78 participants, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03899402, a Phase 2 study of Type 1 Diabetes Mellitus, is active but no longer recruiting, sponsored by State University of New York at Buffalo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Insulin
- DRUG Dapagliflozin
- DRUG Placebo to Dapagliflozin
Study Locations (1)
New York
- Diabetes and Endocrinology Research Center of WNY - Williamsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899402
The ClinicalTrials.gov registry entry for NCT03899402 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (44% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT03899402 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03899402 about?
NCT03899402 is a clinical study titled "Triple Therapy in T1DM". To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
What is the current status of trial NCT03899402?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2019-05-01. Estimated completion is 2026-03-31.
What conditions does trial NCT03899402 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT03899402?
The interventions under investigation include: Semaglutide (DRUG), Insulin (DRUG), Dapagliflozin (DRUG), Placebo to Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03899402?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899402 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
-
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
RECRUITING · Phase 2
-
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Probiotics in Newly Diagnosed T1D
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.